Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2024 | 5097 | 0.630 |
Why?
|
| Anti-HIV Agents | 8 | 2024 | 1324 | 0.540 |
Why?
|
| Viral Load | 6 | 2024 | 819 | 0.440 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 551 | 0.420 |
Why?
|
| HIV-1 | 4 | 2023 | 1260 | 0.390 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2023 | 656 | 0.250 |
Why?
|
| Child | 9 | 2023 | 2242 | 0.230 |
Why?
|
| Developing Countries | 2 | 2024 | 400 | 0.230 |
Why?
|
| Piperazines | 1 | 2024 | 82 | 0.230 |
Why?
|
| Oxazines | 1 | 2024 | 81 | 0.230 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 85 | 0.220 |
Why?
|
| Pyridones | 1 | 2024 | 100 | 0.220 |
Why?
|
| Drug Substitution | 2 | 2024 | 33 | 0.220 |
Why?
|
| Humans | 15 | 2024 | 14537 | 0.200 |
Why?
|
| Lamivudine | 2 | 2023 | 89 | 0.190 |
Why?
|
| Disease Management | 2 | 2019 | 74 | 0.190 |
Why?
|
| Infant | 7 | 2023 | 2244 | 0.190 |
Why?
|
| Male | 10 | 2024 | 6754 | 0.190 |
Why?
|
| Drug Resistance, Viral | 3 | 2024 | 278 | 0.190 |
Why?
|
| Africa, Southern | 4 | 2023 | 91 | 0.180 |
Why?
|
| Female | 11 | 2024 | 9103 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2024 | 472 | 0.180 |
Why?
|
| Pneumonia | 1 | 2021 | 131 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 195 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2020 | 123 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 276 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2021 | 1748 | 0.160 |
Why?
|
| Genes, Viral | 1 | 2017 | 11 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 34 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 71 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 103 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 472 | 0.130 |
Why?
|
| Adolescent | 5 | 2022 | 2985 | 0.130 |
Why?
|
| South Africa | 7 | 2023 | 7596 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2015 | 10 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.120 |
Why?
|
| Ritonavir | 1 | 2015 | 137 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 336 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 278 | 0.110 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 299 | 0.110 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 62 | 0.100 |
Why?
|
| Risk Factors | 3 | 2022 | 1475 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2023 | 1479 | 0.090 |
Why?
|
| Adult | 4 | 2024 | 5913 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2020 | 175 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 1160 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2022 | 799 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2020 | 967 | 0.070 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2024 | 33 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 1862 | 0.060 |
Why?
|
| Global Health | 1 | 2024 | 193 | 0.050 |
Why?
|
| Dideoxynucleosides | 1 | 2023 | 29 | 0.050 |
Why?
|
| Zidovudine | 1 | 2023 | 59 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 563 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 18 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 81 | 0.050 |
Why?
|
| Child Health | 1 | 2021 | 77 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 370 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 254 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.040 |
Why?
|
| Alkynes | 1 | 2020 | 117 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2020 | 123 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 480 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1192 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 418 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2017 | 13 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 16 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2017 | 55 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 72 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 150 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 151 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 306 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 385 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 153 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 231 | 0.030 |
Why?
|
| Darunavir | 1 | 2015 | 12 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 1740 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.030 |
Why?
|
| Thinness | 1 | 2013 | 18 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 163 | 0.030 |
Why?
|
| Caregivers | 1 | 2013 | 76 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 3601 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 507 | 0.020 |
Why?
|